Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

作者：Ning Peng, Linfeng Mao, Jia‐Yong Su, Shaoping Liu, Jun‐Jie Ou, Shuchang Chen, Ze Su, Wenfeng Li, Fuquan Yang, Yong-Heng Zhou, Le Li, Jian‐Hong Zhong · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1669840 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Cancer Mechanisms and Therapy

Corrigendum on: Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection. Front. Immunol. 16:1593153. doi: 10.3389/fimmu.2025.1593153 In the published article, there was an error in Supplementary Tables 1 and2. Several units and the order in which the baseline variables appear are written incorrectly. The correct material statement appears below. The red font represents the modified content. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.1. In the published article, there was an error. In the abstract, the hazard ratio of 1.46 was erroneous due to a typographical mistake. The accurate hazard ratio value is 1.046.